Indirect meta-analysis of randomised placebo-controlled clinical trials of rasagiline and selegiline in the symptomatic treatment of parkinsons disease;Indirekte Metaanalyse randomisierter plazebokontrollierter klinischer Studien zu Rasagilin und Selegilin in der symptomatischen Behandlung der Parkinson-Krankheit

Aktuelle Neurologie

Volumn 38, Issue 5, 2011, Pages 242-252

  Jost, W H ^a   Friede, M ^b   Schnitker, J ^c  

^a DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^b Lundbeck GmbH   (Germany)

^c Inst für Angewandte Statistik   (Germany)

Author keywords

clinical trials; meta analysis; Parkinsons disease; rasagiline; selegiline

Indexed keywords

RASAGILINE; SELEGILINE;

ARTICLE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HALLUCINATION; HUMAN; IDIOPATHIC DISEASE; META ANALYSIS; MONOTHERAPY; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYNCOPE; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 80052462113     PISSN: 03024350     EISSN: 14389428     Source Type: Journal    
DOI: 10.1055/s-0031-1284393     Document Type: Article

References (48)

1. Leitlinien der Deutschen Gesellschaft für Neurologie. 4. berarbeitete Auflage. Stuttgart, New York Thieme: 2008
2. th 2010
3. Brunton L, Parker K, Blumentahl D. et al., Hrsg Goodman and Gilmans Manual of Pharmacology and Therapeutics. New York: McGraw-Hill: 2007;343.
4. Leegwater-Kim J, Bortan E. The role of rasagiline in the treatment of Parkinsons disease. Clin Interv Aging: 2010; 5 149 156
5. Olanow CW, Rascol O, Hauser R et al. A double-blind, delayed-start trial of rasagiline in Parkinsons disease. N Engl J Med: 2009; 361 1268 1278
6. Bar-Am OB, Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett: 2004; 355 169 172 (Pubitemid 38368730)
7. Glenny AM, Altman DG, Song F et al. Indirect comparisons of competing interventions. Health Technol Assess: 2005; 9 1 134 iiiiv
8. Schttker B, Lhmann D, Boulkhemair D et al. Indirekte Vergleiche von Therapieverfahren. Schriftenreihe Health Technology Assessment (HTA) in der Bundesrepublik Deutschland Bd 88. Kln: 2009; Deutsches Institut für Medizinische Dokumentation und Information (DIMDI) 10.3205/hta000071L
9. Song F, Altman DG, Glenny AM et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ: 2003; 326 7387 472 10.1136/bmj.326.7387.472
10. Higgins JPT, Green S. eds Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. updated September 2009). Section 6: Searching for studies. The Cochrane Collaboration: 2009; www.cochrane-handbook.org
11. Higgins JPT, Green S. eds Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. updated September 2009). Section 16.6.2: Indirect comparisons. The Cochrane Collaboration: 2009; www.cochrane-handbook.org
12. Higgins JPT, Green S. eds Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. updated September 2009). Section 9: Analysing data and undertaking meta-analyses. The Cochrane Collaboration: www.cochrane- handbook.org
13. Macleod AD, Counsell CE, Ives N et al. Monoamine oxidase B inhibitors for early Parkinsons disease. Cochrane Database Syst Rev: 2005; 20 CD004898
14. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials: 1996; 17 1 12 (Pubitemid 26120810)
15. Verhagen AP, de Vet HC, de Bie RA et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol: 1998; 51 1235 1241 (Pubitemid 29009523)
16. Fahn S, Elton R. Members of the UPDRS Development Committee. In: Fahn S, Marsden CD, Calne DB, Goldstein M. Hrsg Recent Developments in Parkinsons Disease. Vol 2 Florham Park, NJ Macmillan Health Care Information: 1987; 3163 293 304
17. Siderowf A, McDermott M, Kieburtz K et al. Test-retest reliability of the unified Parkinsons disease rating scale in patients with early Parkinsons disease: results from a multicenter clinical trial. Mov Disord: 2002; 17 758 763 (Pubitemid 41295020)
18. Yahr MD, Duvoisin RC, Schear MJ et al. Treatment of parkinsonism with levodopa. Arch Neurol: 1969; 21 343 354
19. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinsons disease. In: Gillingham FJ, Donaldson IML. Hrsg Third Symposium of Parkinsons Disease. Edinburgh E & S Livingston: 1969
20. Rabey JM, Sagi I, Huberman M et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinsons disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol: 2000; 23 324 330 (Pubitemid 32047014)
21. Parkinson Study Group A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol: 2002; 59 1937 1943
22. Rascol O, Brooks DJ, Melamed E et al. LARGO study group Rasagiline as an adjunct to levodopa in patients with Parkinsons disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet: 2005; 365 947 954 (Pubitemid 41071428)
23. Stern MB, Marek KL, Friedman J et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinsons disease patients. Mov Disord: 2004; 19 916 923 (Pubitemid 39199258)
24. Parkinson Study Group A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol: 2005; 62 241 248
25. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinsons disease. Science: 1989; 245 519 522 (Pubitemid 19204003)
26. Shults CW. Effect of selegiline (deprenyl) on the progression of disability in early Parkinsons disease. Parkinson Study Group. Acta Neurol Scand Suppl: 1993; 146 36 42 (Pubitemid 23251607)
27. Myllyl VV, Sotaniemi KA, Hakulinen P et al. Selegiline as the primary treatment of Parkinsons disease a long-term double-blind study. Acta Neurol Scand: 1997; 95 211 218 (Pubitemid 27211741)
28. Allain H, Pollak P, Neukirch HC. Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial. Mov Disord: 1993; 8 01 S36 S40 (Pubitemid 23355760)
29. Nappi G, Martignoni E, Horowski R et al. Lisuride plus selegiline in the treatment of early Parkinsons disease. Acta Neurol Scand: 1991; 83 407 410
30. Olanow CW, Hauser RA, Gauger L et al. The effect of deprenyl and levodopa on the progression of Parkinsons disease. Ann Neurol: 1995; 38 771 777
31. Larsen JP, Boas J, Erdal JE. Does selegiline modify the progression of early Parkinsons disease? Results from a five-year study. The Norwegian-Danish Study Group. Eur J Neurol: 1999; 6 539 547 (Pubitemid 30028808)
32. Plhagen S, Heinonen EH, Hgglund J et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology: 1998; 51 520 525 (Pubitemid 28406331)
33. Zhao Wu-wie He, Xiao-jun, Zhang Zhi-feng et al. Influence of selegiline on dopaminergic neurons in patients with early Parkinson disease. Chinese J Clin Rehab: 2005; 9 190 192
34. Golbe LI. Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinsons disease. Neurology: 1989; 39 1109 1111 (Pubitemid 19217485)
35. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinsons disease. Parkinsons Disease Research Group of the United Kingdom. BMJ: 1995; 311 1602 1607 (Pubitemid 26002705)
36. Dalrymple-Alford JC, Jamieson CF, Donaldson IM. Effects of selegiline (deprenyl) on cognition in early Parkinsons disease. Clin Neuropharmacol: 1995; 18 348 359
37. Kirollos C, Charlett A, Bowes SG et al. Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinsonism. Eur J Clin Pharmacol: 1996; 50 7 18 (Pubitemid 26140088)
38. Przuntek H, Conrad B, Dichgans J et al. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol: 1999; 6 141 150 (Pubitemid 29141895)
39. Takahashi M, Yuasa R, Imai T et al. Selegiline (L-deprenyl) and L-dopa treatment of Parkinsons disease: a double-blind trial. Intern Med: 1994; 33 517 524 (Pubitemid 24309221)
40. Ives NJ, Stowe RL, Marro J et al. Monoamine oxidase type B inhibitors in early Parkinsons disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ: 2004; 329 7466 593. Epub 2004 Aug 13. 10.1136/bmj.38184.606169.AE (Pubitemid 39256543)
41. Institut für Qualitt und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Memantin bei Alzheimer Demenz: Ergebnisse der unpublizierten Studien IE2101 und MEM-MD-22 sowie unpublizierter Responderanalysen. IQWiG-Berichte Nr. 74: 2010; http://www.iqwig.de/download/Arbeitspapier-zu-Memantin-bei-Alzheimer- Demenz.pdf
42. Borenstein M, Hedges L, Rothstein H. Meta-analysis. Fixed effects vs. Random effects: 2007; www.meta-analysis.com
43. Senn S. Statistical Issues in Drug Development. Chichester John Wiley & Sons; 1997
44. Senn S. The many modes of meta. Drug Information Journal: 2000; 34 535 549 (Pubitemid 30351006)
45. Senn S. Trying to be precise about vagueness. Stat Med: 2007; 26 1417 1430 (Pubitemid 46403201)
46. Schrag A, Sampaio C, Counsell N et al. Minimal clinically important change on the unified Parkinsons disease rating scale. Mov Disord: 2006; 21: 1200 1207 (Pubitemid 44336608)
47. Knudsen-Gerber DS. Selegiline and rasagiline: twins or distant cousins? Guidel Cosnult Pharm: 2011; 26 48 51
48. Callaghan RC, Cunningham JK, Sajeev G et al. Incidence of Parkinsons disease among hospital patients with methamphetamine-use disorders. Mov Disord: 2010; 25 2333 2339